|
SK biopharm is a global pharmaceutical company focused on the research, development, and commercialization of drugs, primarily in the central nervous system (CNS) and oncology sectors. The company’s core product is cenobamate, an antiepileptic drug marketed as XCOPRI in the United States and ONTOZRY in Europe, which is sold directly in the US through its subsidiary SK Life Science, Inc. and licensed to partners in other regions. SK biopharm also developed solriamfetol, a wakefulness-promoting agent marketed as SUNOSI, which is commercialized by partners such as Axsome Therapeutics. The company is expanding its pipeline into radiopharmaceutical therapy and targeted protein degradation, having acquired SK Life Science Labs to secure targeted protein degradation capabilities. SK biopharm licenses its drug candidates to partners in Europe, Asia, Canada, Latin America, and the Middle East, including Arvelle, Otsuka Pharmaceutical, Ignis Therapeutics, Endo Operations, Dexcel, Eurofarma, Hikma MENA, and Dong-A ST. The company collaborates with SK Biopharmaceuticals for the supply of active pharmaceutical ingredients and contract manufacturing services. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage skbp.com |
| Sector Healthcare | IR page — | |
|
Tags
central nervous system, epilepsy, sleep disorders, radiopharmaceutical therapy, targeted protein degradation, oncology, neurology, psychiatry, innovative drugs, license-out, clinical development, XCOPRI, ONTOZRY, SUNOSI, cenobamate, solriamfetol, carisbamate, SKL13865, SKL20540, SKL24741, SKL35501, SKL37321, SK Life Science Inc., SK Life Science Labs Inc., SK Biopharmaceuticals, Axsome Therapeutics, Arvelle, Angelini, Otsuka Pharmaceutical, Ignis Therapeutics, Endo Operations, Knight Therapeutics, Dexcel, Eurofarma, Hikma MENA FZE, Dong-A ST, LifeSci Venture Partners, Mentis Care, Medsyn, Jazz Pharmaceuticals, Aerial Biopharma, Paladin Labs
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 6.179T |
| Market cap (USD) | $ 4.547B |
| P/E | 15.41 |
| PEG | — |
| P/BV | 6.05 |
| P/S | 7.17 |
| P/OCF | 24.87 |
| P/FCF | 25.67 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 39.3% |
| ROI | 32.8% |
| ROIC | 25.1% |
| Profit margin | 37.8% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 40.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 706.741B | 547.596B | 354.892B | 246.179B | 418.645B | 25.999B | 123.852B | 1.099B |
| Net profit | 266.95B | 240.738B | -35.379B | -139.431B | 64.846B | -247.414B | -71.519B | -138.096B |
| Free cash flow | 169.442B | 93.505B | -96.586B | -164.831B | -97.188B | -221.749B | -94.534B | -142.717B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||
| Trade receivables (KRW) | — | 189M | 8.56B | 55.9B | 63.5B | 111B | 174B | 229B |
| ↳ YoY growth | +4,420.2% | +552.6% | +13.6% | +74.8% | +56.6% | +31.6% | ||
| ↳ 5y CAGR | +291.3% | +92.9% | ||||||
| Other receivables (KRW) | 1.2B | 759M | 2.56B | 900M | 124M | 2.22B | — | — |
| Borrowings, current (KRW) | — | 100B | — | — | — | 50B | 151B | 0.00 |
| Borrowings, non-current (KRW) | — | — | — | — | 144B | 94.5B | 0.00 | 0.00 |
| Lease liabilities (KRW) | — | 9.06B | 18.5B | 15.7B | 12.2B | 33.6B | 33.8B | 48.9B |
| Cash and deposits (KRW) | 74.3B | 51.1B | 59.3B | 226B | 104B | 240B | 323B | 308B |
| Intangible assets (KRW) | 246M | 883M | 19.7B | 18.9B | 17.2B | 27B | 32.5B | 51.2B |
| Right-of-use assets (KRW) | — | — | — | — | 12.4B | 34.1B | 31.9B | 45.6B |
| Net debt (borrowings + leases - cash) (KRW) | — | 57.9B | — | — | 51.8B | -61.6B | -289B | -259B |
| Cash flow detail | ||||||||
| Operating cash flow (KRW) | -141B | -81.3B | -211B | -92.9B | -160B | -94.2B | 94.9B | 176B |
| Purchases of property, plant and equipment (KRW) | -1.44B | -13.2B | -11B | -4.32B | -4.91B | -2.39B | -1.4B | -6.89B |
| Purchases of intangible assets (KRW) | — | -848M | -3.31B | -1.68B | -1.05B | -864M | -12B | -22.6B |
| Interest paid (cash effect) (KRW) | — | -1.23B | -4.44B | -844M | -3.49B | -8.14B | -9.5B | -6.44B |
| Income taxes paid (cash effect) (KRW) | -36M | -708M | -6.39B | -6.16B | -4.68B | -8.13B | -12.2B | -20B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -143B | -95.4B | -225B | -98.9B | -166B | -97.5B | 81.5B | 147B |
| Income detail | ||||||||
| Total comprehensive income (KRW) | -139B | -71.7B | -253B | — | -128B | -34.8B | 253B | 252B |
| Comprehensive income to owners (KRW) | — | — | — | — | -128B | -32.9B | 263B | 267B |
| Reported | Mar 16, 2021 | Mar 16, 2021 | Mar 16, 2021 | Mar 18, 2024 | Mar 18, 2025 | Mar 18, 2025 | Aug 14, 2025 | Mar 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding SK biopharm
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DFSE | 0.03% | 2,524 | $ 166.186K | Nov 12, 2026 |
| DEHP | 0.02% | 1,469 | $ 96.722K | Nov 12, 2026 |
| DFAE | 0.01% | 17,954 | $ 1.182M | Nov 12, 2026 |
| AVSE | 0.01% | 295 | $ 19.25K | Nov 16, 2026 |
| AVXC | 0.01% | 329 | $ 21.468K | Nov 16, 2026 |
| DFAX | 0.01% | 13,649 | $ 898.683K | Nov 12, 2026 |
| DFEM | 0.01% | 9,127 | $ 600.943K | Nov 12, 2026 |
| DEXC | 0.00% | 143 | $ 9,415.46 | Nov 12, 2026 |
| AVEM | 0.00% | 3,545 | $ 231.322K | Nov 16, 2026 |